CVE:ACST - Acasti Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.94 -0.04 (-4.08 %)
(As of 06/24/2018 04:00 PM ET)
Previous CloseC$0.94
Today's RangeC$0.94 - C$1.05
52-Week RangeC$0.77 - C$2.99
Volume59,900 shs
Average Volume71,329 shs
Market CapitalizationC$33.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolCVE:ACST
CUSIPN/A
Phone+1-450-6864555

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-162.34%
Return on Assets-103.36%

Miscellaneous

EmployeesN/A
Outstanding Shares25,638,000

The Truth About Cryptocurrencies

Acasti Pharma (CVE:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

Who are some of Acasti Pharma's key competitors?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:
  • Ms. Janelle D' Alvise, CEO, Pres & Director
  • Ms. Linda P. O'Keefe, CFO & Sec.
  • Dr. Pierre Lemieux, Chief Operating Officer
  • Mr. Laurent Harvey, VP of Clinical & Non-Clinical Affairs
  • Mr. Brian James Groch, Chief Commercial Officer (Age 51)

Has Acasti Pharma been receiving favorable news coverage?

Press coverage about ACST stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Acasti Pharma earned a news impact score of -0.02 on Accern's scale. They also assigned press coverage about the company an impact score of 44.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$0.94.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of C$33.54 million.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.


MarketBeat Community Rating for Acasti Pharma (ACST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.